Form 4: Shattuck Labs Chief Medical Officer Reports Stock Transactions

Shattuck Labs' Chief Medical Officer, Arundathy N. Pandite, reported the disposition of 3,211 shares and the acquisition of 206,200 stock options.

Summary

• Arundathy N. Pandite, Chief Medical Officer of Shattuck Labs, reported a transaction involving the company's stock.
• On January 25, 2025, Ms. Pandite disposed of 3,211 shares of common stock at a price of $1.16 per share.
• On January 28, 2025, Ms. Pandite acquired 206,200 stock options with an exercise price of $1.18 per share.
• These options vest over time, with one quarter vesting on January 28, 2026, and the remaining three quarters vesting monthly through January 28, 2029, contingent on continued service.

Sentiment

Score: 5

Explanation: The document is a neutral report of stock transactions, with no indication of positive or negative sentiment.

Industry Context

This is a routine filing related to insider transactions and is common for publicly traded companies. It does not indicate any specific trend in the biotech industry.

Comparison to Industry Standards

• Stock option grants and disposals are standard practice for executive compensation in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of the options is typical, designed to incentivize long-term performance and retention of key personnel.
• The reported transactions are consistent with standard SEC Form 4 filings for insider trading.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, as they reflect insider activity.
• The vesting schedule of the options is designed to align the executive's interests with those of the shareholders.

Key Dates

Keywords

Shattuck Labs, stock options, insider trading, Form 4, equity, Chief Medical Officer, Arundathy N. Pandite